《大行報告》瑞信上調錦欣生殖(01951.HK)目標價至21.2元 評級「跑贏大市」
瑞信發表報告指,錦欣生殖(01951.HK)近日公布入股雲南省昆明盤龍區的民營營利性二級綜合醫院九洲醫院和雲南省昆明五華區的民營營利性三級婦產專科醫院萬家醫院,將間接享有該等醫院約19.33%的經濟利益。
該行指交易估值合理,其中一間收購醫院是雲南第二大試管嬰兒醫院,兩間醫院的潛在產能可能增加兩倍以上。
瑞信表示,考慮到這項交易和未來潛在併購的積極影響,維持錦欣生殖「跑贏大市」評級,並將目標價由18.5元調高至21.2元。該行又指,錦欣生殖的目標是在今年下半年實現1至2項大型交易, 相信併購活動將繼續成為公司下半年的一個潛在催化劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.